The risk of major bleeding event in patients with chronic kidney disease on pentoxifylline treatment

doi:10.1038/s41598-021-92753-4

Chia Nan University of Pharmacy & Science Institutional Repository > 藥理學院 > 藥學系(所) > 期刊論文 > Item 310902800/34403

請使用永久網址來引用或連結此文件: https://ir.cnu.edu.tw/handle/310902800/34403

標題:	The risk of major bleeding event in patients with chronic kidney disease on pentoxifylline treatment
作者:	Fang, Jing-Hung Chen, Yi-Chen Ho, Chung-Han Chen, Jui-Yi Hsing, Chung-Hsi Liang, Fu-Wen Wu, Chia-Chun
貢獻者:	Chi Mei Med Ctr, Dept Nephrol Chi Mei Med Ctr, Dept Med Res Chi Mei Med Ctr, Dept Anaesthesiol Kaohsiung Med Univ, Coll Hlth Sci, Dept Publ Hlth Kaohsiung Med Univ Hosp, Dept Med Res Chia Nan Univ Pharm & Sci, Dept Pharm
關鍵字:	RETROSPECTIVE-COHORT ASPIRIN HEMORRHAGE WOMEN SCORE MEN
日期:	2021
上傳時間:	2023-11-11 11:49:58 (UTC+8)
出版者:	NATURE RESEARCH
摘要:	Patients with chronic kidney diseases (CKD) are often treated with antiplatelets due to aberrant haemostasis. This study aimed to evaluate the bleeding risk with CKD patients undergoing pentoxifylline (PTX) treatment with/without aspirin. In this retrospective study, we used Taiwan's National Health Insurance Research Database to identify PTX treated CKD patients. Patients undergoing PTX treatment after CKD diagnosis were PTX group. A 1:4 age, sex and aspirin used condition matched CKD patients non-using PTX were identified as controls. The outcome was major bleeding event (MBE: intracranial haemorrhage (ICH) and gastrointestinal tract bleeding) during 2-year follow-up period. Risk factors were estimated using Cox regression for overall and stratified analysis. The PTX group had higher MBE risk than controls (hazard ratio (HR) 1.19; 95% confidence interval (CI) 0.94-1.50). In stratified analysis, hyperlipidaemia was a significant risk factor (HR: 1.42; 95% CI 1.01-2.01) of MBE. A daily PTX dose larger than 800 mg, females, non-regular aspirin usage, and ischaemic stroke were risk factors for MBE in PTX group. When prescribing PTX in CKD patients, bleeding should be closely monitored, especially in those with daily dose more than 800 mg, aspirin users, and with a history of ischaemic stroke.
關聯:	SCI REP-UK, v.11, n.1
顯示於類別:	[藥學系(所)] 期刊論文

文件中的檔案:

檔案	描述	大小	格式	瀏覽次數
index.html		0Kb	HTML	264	檢視/開啟
s41598-021-92753-4.pdf		1073Kb	Adobe PDF	106	檢視/開啟

在CNU IR中所有的資料項目都受到原著作權保護.

TAIR相關文章

資料載入中.....